John E. Harris, MD, PhD
Research Focus - Using Vitiligo Pathogenesis to Develop Novel Insights into Better Approaches for Melanoma Immunotherapy
- Vitiligo is an autoimmune disease of the skin that results in melanocyte destruction
- Vitiligo patients have a 3-fold lower risk of developing melanoma
- Melanoma immunotherapy using checkpoint inhibitors frequently induces vitiligo, which indicates a better response to treatment
- We have acquired a thorough understanding of vitiligo pathogenesis, and we are using these insights to develop targeted melanoma immunotherapies
Representative Publication
Fakuda K, Okamura K, Riding RL, et al. AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma. J Exp Med. 2021;218(9):e20200962.
In the News
Getting Results…
-
Read more
-
UMass Chan kicks off 2024 academic year with weeklong Convocation celebration
Read more -
Six new endowed chairs named at UMass Chan Medical School
Read more -
UMass Chan BRIDGE Fund invests nearly $2M in 13 faculty projects
Read more -
Clinical study aims to identify early molecular and biological signatures of vitiligo
Read more -
Craig Ceol receives NIH grant to study melanocyte regeneration
Read more -
UMass Cancer Center funds five UMass Chan research projects
Read more -
John Harris appointed chair of dermatology
Read more -
John Harris receives Presidential Early Career Award for Scientists
Read more -
Top story: John Harris lab identifies new pathway to reverse vitiligo
Read more -
John Harris lab identifies new pathway to reverse vitiligo
Read more -
John Harris sheds light on treatments for vitiligo in WBZ-TV segment
Read more -
New treatment in the works for disfiguring skin disease, vitiligo
Read more -
UMass Medical School vitiligo expert discusses common skin condition
Read more -
Telegram story raises awareness of vitiligo, an autoimmune disease afflicting 70 million people
Read more